huMAb OX40L
DrugIntravenous repeating dose
NCT Number: NCT00983658
This Phase II, double-blind, placebo-controlled, randomized, parallel-group study is designed to evaluate the efficacy, safety, and tolerability of huMAb OX40L administered to patients by IV infusion for the treatment of allergen-induced asthma.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous repeating dose
Intravenous repeating dose
Time frame: 16 weeks after the first dose
Time frame: Approximately Day 56 prior to third dose
Time frame: 24 hours after each allergen challenge
Time frame: Between 0 and 2 hours after each allergen challenge
Time frame: Through study completion or early study discontinuation
Time frame: Through study completion or early study discontinuation
Time frame: Through study completion or early study discontinuation
Time frame: Through study completion or early study discontinuation
Time frame: Through study completion or early study discontinuation
Time frame: Through study completion or early study discontinuation
Genentech, Inc.
Industry
A Phase II, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous huMAb OX40L (RO4989991) in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05476484
Allergic Rhinitis, Allergy
Hørsholm, Copenhagen, Denmark
View Trial DetailsNCT07427576
Asthma, Bronchial Diseases
Santa Cruz de Tenerife, Canary Islands, Spain
View Trial DetailsNCT00114881
Allergy, Asthma
Baltimore, Maryland, United States
View Trial DetailsNCT05685381
Asthma, Bronchial Diseases
Beacon, New York, United States
View Trial Details